Home - IO Biotech
Pioneering off-the-shelf dual-action therapeutic cancer vaccines with the goal of improving outcomes for people with melanoma and other tumor types.
IO Biotech, Inc. (IOBT) - Yahoo Finance
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
IO Biotech, Inc. - Invest in combination cancer therapy
Dec 20, 2024 · IO Biotech is a clinical-stage biopharmaceutical company pioneering the first dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of …
IO Biotech - LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform.
IO Biotech Announces Positive Results from Phase 2 Trial of …
NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic …
IO Biotech, Inc. - IO Biotech Announces Positive Results from …
Sep 14, 2024 · IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive …
IO Biotech Announces Publication of Preclinical Data Investigating ...
Feb 4, 2025 · IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win ® platform. …
IO Biotech Completes Enrollment in Phase 2 Trial of its …
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic …
News - IO Biotech
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate
IO Biotech, Inc. (IOBT) Stock Price, Quote & News - Stock Analysis
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.